Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on November 12, 2015. The filing serves to announce the Company's financial results for the third quarter of 2015. The registrant is incorporated in Delaware with principal executive offices in Bothell, Washington.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued in a press release (Exhibit 99.1), but the specific financial data points are not contained within the body of this 8-K text.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document references the issuance of Q3 2015 results but does not summarize the variances or trends within the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It strictly references the attached press release for the announcement of results. The text includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release dated November 12, 2015) to obtain actual revenue, net loss, and cash position figures.
- Verify the specific details of the third-quarter 2015 operational results, as they are not summarized in the 8-K body.
- Confirm the status of the Company's liquidity and capital resources by reading the full press release referenced in Item 2.02.